Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Could it be that we end up with Apabetalone having a statistically significant impact on Kidney disease and Dementia...but relative risk reduction on MACE rates fall short of 30%? 30% sounds extremely impressive if it happens...but would a 15% rate work for the FDA?
If my memory serves me right, then the statins had a 15% RRR in their Phase 3 trials.
